Lexicon Pharmaceuticals (LXRX) Announces 22% Reduction in Workforce
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announceda restructuring of its operations to conserve capital and direct resources towards its most advanced drug discovery and development programs. The restructuring will involve a workforce reduction of 102 employees, primarily in basic research, early-stage discovery and support positions, representing approximately 22% of its total workforce.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.[SM]
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.[SM]
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- IntercontinentalExchange (ICE) says daily crude volume hits record in May
- New York Mortgage Trust (NYMT) Prices 2.75M Offering at $6.65/Share
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
LayoffsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
